Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Desmopressin

DDAVP · ADH Synthetic Analog

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

Desmopressin is a synthetic vasopressin (ADH) V2-receptor analog with an FDA label and decades of randomized evidence for central diabetes insipidus, primary nocturnal enuresis, perioperative hemostasis in mild hemophilia A and type 1 von Willebrand disease, and (via Noctiva, approved March 2017) nocturia due to nocturnal polyuria; grade 5 applies to those approved indications. The separate off-label memory-enhancement use rests on a small, dated set of studies (single-case neurosurgical reports and a 50-patient ECT trial) with no regulatory approval and no consensus, and on its own would grade roughly grade 1 to grade 2.

FDA
FDA Approved. Central diabetes insipidus, primary nocturnal enuresis, perioperative hemostasis in mild hemophilia A and type 1/2M von Willebrand disease, and nocturia due to nocturnal polyuria (Noctiva, 2017). NOT approved for memory or cognitive enhancement.
WADA
Prohibited. On the WADA list as a masking agent (plasma-volume expander that can dilute urine and mask other doping agents).

Reference only. Not medical advice.

What can go wrong

Hyponatremia and water intoxication, which can progress to seizures, coma and death; restrict fluids around dosing. Not for unsupervised off-label memory use.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Desmopressin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A synthetic antidiuretic-hormone (vasopressin) V2-receptor analog, FDA-approved for central diabetes insipidus, bedwetting, nocturia due to nocturnal polyuria, and perioperative bleeding control in mild hemophilia A and type 1 von Willebrand disease. It also triggers release of factor VIII and von Willebrand factor. Off-label memory-enhancement use is experimental and rests on limited, dated human data.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Diabetes insipidus (approved)
  • Memory enhancement (off-label, experimental)
Central diabetes insipidus
Replacement for the missing antidiuretic hormone, concentrating urine and controlling excessive urination and thirst.
Bedwetting and nocturia
A standard treatment for primary nocturnal enuresis in children and adults and for nighttime urination from nocturnal polyuria.
Bleeding disorders
At higher doses, used for mild hemophilia A, type 1 von Willebrand disease and uremic bleeding by releasing stored clotting factors.

How it works

Desmopressin is a tweaked copy of vasopressin, the body’s water-conserving hormone, and it does two quite different things. As an antidiuretic, it tells the kidneys to reabsorb water, concentrating urine and cutting how much you produce, which is why it treats conditions of excessive or poorly-controlled urination. At higher doses it also does something unrelated: it prompts the lining of blood vessels to release stored clotting factors, briefly boosting the blood’s ability to clot. One molecule, two jobs, depending on the dose.

Desmopressin is a synthetic analog of arginine vasopressin, the antidiuretic hormone, modified at two positions so it acts selectively on the kidney’s V2 receptor and lasts longer, while shedding the blood-pressure-raising effect of natural vasopressin. Sold as DDAVP, it comes as a nasal spray, tablet, sublingual form and injection, with very different absorption by route.

Type
Vasopressin analog (V2)
Job 1
Antidiuretic
Job 2
Releases clotting factors
Routes
Nasal, oral, injection
Approved
Yes (DDAVP)
Key risk
Hyponatremia

Two Unrelated Jobs From One Peptide

Desmopressin is a quietly useful, long-established medicine, and what makes it interesting is its double life from a single, elegant design. Native vasopressin both conserves water and constricts blood vessels; desmopressin keeps the water-conserving action, made selective and longer-lasting, while dropping the blood-pressure effect. That gives it two well-validated roles. As an antidiuretic it is the replacement for central diabetes insipidus and a standard treatment for bedwetting and for nighttime urination. At higher doses it releases stored von Willebrand factor and factor VIII from blood-vessel walls, making it a go-to for mild hemophilia A, type 1 von Willebrand disease and bleeding from kidney failure. The one thing to respect is its mechanism’s flip side: by making the body hold water, it can dilute blood sodium to dangerous levels, so fluid intake and sodium need watching, especially in the elderly, young children and the nighttime-urination use.

Safety in detail

Hyponatremia is the central safety concern across every desmopressin formulation. In December 2007 the FDA removed the intranasal (nasal-spray) formulations from the primary-nocturnal-enuresis (bedwetting) indication after 61 postmarketing cases of hyponatremia-associated seizures, including two deaths, with a large share in children; oral tablet forms remained available for enuresis. The Noctiva nocturia nasal spray approved in 2017 carries a boxed warning for hyponatremia and requires checking serum sodium before starting, within about a week, and around a month. Fluid intake is generally restricted from roughly 1 hour before to 8 hours after a dose, and the drug is contraindicated in patients at high hyponatremia risk.

  • Its central risk is hyponatremia, low blood sodium from water retention, which can cause seizures and water intoxication.
  • Fluid intake and sodium need monitoring, especially in the elderly, young children and the nighttime-urination use.
  • Nighttime-urination products carry a boxed hyponatremia warning and a caution against use in older adults.
  • It is otherwise well tolerated, with headache, nausea or nasal effects, and its clotting effect can fade with repeated dosing.
  • It does not work for nephrogenic diabetes insipidus and is used cautiously in severe kidney impairment.

Children and teenagers

Desmopressin has a genuine, important pediatric use: bedwetting, primary nocturnal enuresis, is a major pediatric indication and a standard treatment, alongside pediatric diabetes insipidus and bleeding disorders, under medical supervision. The hyponatremia and fluid caution matters especially in children, with bedtime fluid restriction and oral forms often preferred over nasal for enuresis. It is a legitimate, supervised pediatric medicine.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Desmopressin’s economy is a broad, mature one: the original brand, widespread generics across multiple formulations, and newer branded products for nighttime urination. It serves several distinct clinical markets, from diabetes insipidus to bedwetting to bleeding disorders, and it is largely inexpensive, a long-established medicine rather than a marketing-driven one.

How we got here

Desmopressin is a synthetic analog of the antidiuretic hormone vasopressin, modified for greater potency and a longer duration of action. It was first developed to treat central diabetes insipidus. Its use later expanded to nocturnal enuresis (bedwetting), nocturia due to nocturnal polyuria, and bleeding disorders such as mild hemophilia A and von Willebrand disease.

Desmopressin was created by modifying vasopressin into a selective, longer-acting antidiuretic that drops the hormone’s blood-pressure effect, and it reached the market decades ago, first for central diabetes insipidus, then for bedwetting, and then for bleeding disorders as its clotting-factor-releasing effect was recognized. After roughly forty years of use it became broadly generic, with newer formulations added for nighttime urination, carrying hyponatremia warnings.

  1. 1970sDesmopressin is synthesized as a selective, longer-acting vasopressin analog.
  2. 1970s-1980sIt is marketed first for diabetes insipidus, then for bedwetting.
  3. laterIts clotting-factor-releasing effect extends it to mild bleeding disorders.
  4. decades onIt becomes broadly generic across multiple formulations.
  5. recentNewer nighttime-urination products arrive with hyponatremia warnings.

The numbers behind the grade

Type
Vasopressin analog
Receptor
V2-selective
Job 1
Antidiuretic
Job 2
Hemostatic
Approved
Yes
Key risk
Hyponatremia

The people taking it

A versatile, long-established vasopressin analog used both to control excessive urination, in diabetes insipidus, bedwetting and nocturia, and to boost clotting, in mild hemophilia A, von Willebrand disease and uremic bleeding.

Desmopressin’s users span two clinical worlds: people with diabetes insipidus, children and adults with bedwetting, and older adults with nighttime urination on the antidiuretic side, and people with mild hemophilia A, von Willebrand disease or bleeding from kidney failure on the clotting side. It serves a broad, all-ages population.

Approved for diabetes insipidus, bedwetting and nocturia on the antidiuretic side and for mild hemophilia A, von Willebrand disease and uremic bleeding on the clotting side. A versatile, widely-used standard drug.

Set against the alternatives

Against natural vasopressin, desmopressin keeps the water-conserving action but drops the blood-pressure effect, a more selective tool. Against terlipressin, a vasopressin analog tuned to a different receptor for variceal bleeding and hepatorenal syndrome, it shows how the family is tailored by receptor selectivity. Against bedwetting alarms and behavioral approaches, it is the pharmacologic standard. And against blood-product factor replacement for mild bleeding disorders, it avoids transfusion by mobilizing the patient’s own stored clotting factors. Its strength is versatile, proven utility from an elegant design; its main limit is the hyponatremia risk.

What we do not know

  • How best to minimize the hyponatremia risk, especially for nighttime urination in older adults.
  • Which formulation and route suit each indication best.
  • Its role relative to newer agents in each of its uses.
  • How to balance it against alarms and behavioral approaches for bedwetting.

What could change

Nocturia managementFocus on minimizing hyponatremia risk in the nighttime-urination use.Formulation refinementContinued development of routes and dosing for each indication.Established multi-use roleIts dual antidiuretic and hemostatic roles remain standard.Vasopressin-analog familyRelated analogs continue to be tailored by receptor selectivity.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Desmopressin is a standard, widely-available prescription medicine, mostly generic, the legitimate route. It is effective and versatile, with the key requirement of fluid management and sodium monitoring, particularly in the elderly, children and the nighttime-urination use. It is a well-understood drug, not a gray-market peptide.

Generic desmopressin is inexpensive as a long-established medicine, while the newer branded nighttime-urination products are pricier. Cost is rarely a barrier for the core uses.

Desmopressin comes from regulated pharmaceutical manufacturing, as branded and generic product in multiple formulations, with full quality assurance.

Branded and genericDesmopressin is widely available as branded and generic product.Multiple formulationsIt is supplied as nasal spray, tablet, sublingual form and injection.Standard pharmacy stockIt is a routine prescription drug across pharmacies.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Desmopressin.

Nothing outstanding on this one.

Sources

The studies that matter

  • Antidiuretic mechanismestablished

    Desmopressin stimulates kidney V2 receptors to reabsorb water, concentrating urine and reducing its volume.

  • Diabetes insipidusestablished

    It became the replacement therapy for central diabetes insipidus, the deficiency of natural antidiuretic hormone.

  • Enuresis and nocturiaestablished

    Trials supported its use for bedwetting in children and adults and for nighttime urination from nocturnal polyuria.

  • Hemostatic mechanismestablished

    At higher doses it releases von Willebrand factor and factor VIII from blood-vessel walls, raising clotting-factor levels several-fold.

  • Hyponatremia safetydocumented

    Water retention can lower blood sodium dangerously, leading to boxed warnings on nighttime-urination products and cautions in the elderly.